Loading
Leads the German GMALL group and showed blinatumomab clears residual leukaemia in adults with ALL.
Nicola Gökbuget leads the German Multicenter Study Group for Adult ALL (GMALL), whose trials defined risk-adapted therapy and MRD-guided treatment in adult ALL, and was principal investigator of the BLAST trial showing blinatumomab converts most MRD-positive patients to MRD-negative with improved survival, the basis for its MRD indication. She co-authored the European guidelines on adult ALL.
Shares Blinatumomab, Acute lymphoblastic leukaemia and the tags all, cooperative-group.
Shares Blinatumomab, CD19, T-cell engagers (bispecific), Acute lymphoblastic leukaemia and the tag all.
Shares Blinatumomab, CD19, T-cell engagers (bispecific), Acute lymphoblastic leukaemia and the tag all.
Shares ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission, Blinatumomab, CD19, Acute lymphoblastic leukaemia.
Shares Blinatumomab, T-cell engagers (bispecific), MRD / molecular residual disease testing, Acute lymphoblastic leukaemia and the tag cooperative-group.
Shares ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission, Blinatumomab, CD19, Acute lymphoblastic leukaemia.
Shares Blinatumomab, T-cell engagers (bispecific), Acute lymphoblastic leukaemia.
Shares MRD / molecular residual disease testing, Acute lymphoblastic leukaemia and the tag all.